Wealthfront Advisers LLC Has $3.50 Million Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Wealthfront Advisers LLC raised its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 927.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 33,105 shares of the medical equipment provider's stock after purchasing an additional 29,883 shares during the quarter. Wealthfront Advisers LLC's holdings in Zimmer Biomet were worth $3,497,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Stonebridge Financial Group LLC bought a new position in shares of Zimmer Biomet in the 4th quarter valued at about $25,000. Dunhill Financial LLC lifted its position in Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider's stock worth $26,000 after acquiring an additional 218 shares during the last quarter. Ashton Thomas Securities LLC acquired a new position in shares of Zimmer Biomet in the third quarter valued at about $28,000. Brooklyn Investment Group acquired a new stake in shares of Zimmer Biomet in the third quarter valued at approximately $35,000. Finally, Kentucky Trust Co acquired a new stake in Zimmer Biomet during the fourth quarter worth approximately $39,000. Institutional investors and hedge funds own 88.89% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Raymond James cut their target price on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. Stifel Nicolaus increased their target price on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a report on Thursday, January 23rd. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a "neutral" rating to an "overweight" rating and boosted their target price for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Royal Bank of Canada dropped their price target on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. Finally, Barclays reduced their price objective on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating on the stock in a research report on Monday, February 10th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, Zimmer Biomet has an average rating of "Hold" and a consensus price target of $124.15.

Remove Ads

Insider Activity at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares of the company's stock, valued at approximately $915,379.20. This represents a 14.13 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.95% of the stock is owned by corporate insiders.

Zimmer Biomet Trading Up 1.7 %

ZBH stock traded up $1.88 during midday trading on Monday, hitting $111.85. The stock had a trading volume of 2,435,739 shares, compared to its average volume of 1,484,314. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The firm has a market cap of $22.26 billion, a P/E ratio of 25.13, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04. The business has a fifty day moving average price of $105.83 and a two-hundred day moving average price of $106.92. Zimmer Biomet Holdings, Inc. has a 1-year low of $97.69 and a 1-year high of $133.90.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the prior year, the business posted $2.20 EPS. On average, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.24 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 annualized dividend and a dividend yield of 0.86%. Zimmer Biomet's dividend payout ratio is currently 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.